Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging study of ciclopirox olamine (CPO) solution in seborrhoeic dermatitis of the scalp
2006-000292-15Phase 2Terminated
- Sponsor
- Stiefel Laboratories
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ciclopirox in seborrheic dermatitis (SD) (4 arms), sponsored by Stiefel Laboratories. Primary endpoint: Change in area of seborrhoeic dermatitis on the scalp. Started Feb 2006; status: terminated.
02
Drugs
ciclopirox
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on 2006-000292-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000292-15.